Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endothelial injury biomarker EASIX predicts mortality risk in adults with chronic obstructive pulmonary disease: A retrospective cohort study.

Medicine·2026

Same author

In-situ growth of covalent organic frameworks on 3D-printed monolithic microfluidic chips for online analysis of naphthalene and its metabolites in cells.

Analytica chimica acta·2026

Same author

Vagus nerve stimulation for patients with tuberous sclerosis complex-related drug-resistant epilepsy: A prospective cohort study.

Epilepsia·2026

Same author

Keap1-Inhibitory Peptides from <i>Ganoderma lucidum</i> Spores: Virtual Enzymolysis, Fragmentomics and Antioxidant Mechanism.

Molecules (Basel, Switzerland)·2026

Same author

Comparative Analysis of Full-Length Reference Gene Stability in <i>Phoebe zhennan</i> Under Primary Abiotic and Biotic Stresses.

Plants (Basel, Switzerland)·2026

Same author

Surfactant-free polymer microspheres with molecular confinement-enabled optical encoding for dual-color immunochromatographic assays.

Mikrochimica acta·2026

Search research articles

Related Experiment Video

Updated: May 30, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Gastric cancer patient with MET amplification treated with crizotinib achieves long-term survival: a case report.

Weifeng Xu^1,2, Caiyun Nie¹, Hui Wang³

¹Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China.

AME Case Reports

|January 27, 2025

Summary

Crizotinib initially benefited a gastric cancer patient with MET amplification, but resistance developed. Trametinib effectively inhibited tumor growth in a miniPDX model, offering a new treatment option for advanced gastric cancer.

Keywords:

Gastric cancer (GC)KRAS MET amplification case report crizotinib

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: May 30, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

Oncology
Genetics
Pharmacology

Background:

Gastric cancer (GC) is a leading cause of cancer mortality globally, with advanced stages having a poor prognosis.
Targeted therapies have improved survival rates for GC patients.
Crizotinib, an unapproved drug, has shown potential benefits in select GC cases.

Observation:

A patient with advanced gastric cancer and MET amplification initially responded well to crizotinib for 34 months, achieving a high quality of life.
The patient developed resistance to crizotinib, with new mutations including TP53 and KRAS amplification.
A mini patient-derived xenograft (miniPDX) mouse model was utilized for rapid drug sensitivity testing.

Findings:

Trametinib demonstrated significant inhibition of tumor cell growth in the miniPDX model, indicating its potential efficacy.
The patient achieved a good quality of life for three years, which is a rare outcome in advanced GC cases.

Implications:

This case highlights the potential of targeted therapy sequencing in managing advanced gastric cancer.
MiniPDX models offer a promising approach for personalized drug screening and treatment selection in refractory cancers.
Further research into trametinib's role in overcoming crizotinib resistance in MET-amplified GC is warranted.